Scinai Lands $5.1M CDMO Deal, Expanding Clinical Manufacturing Footprint
SCNI is trading near its 52-week low of $1.06 (6.6% above the low).
Summary
Scinai signed a $5.1 million development and clinical manufacturing agreement, expanding its CDMO business. This follows the H1 2026 filing that showed $3.1M in committed orders and a new U.S. clinical manufacturing facility. The deal adds a material revenue stream for a company with a market cap around $661K, and it comes after the company regained Nasdaq compliance and completed a 1-for-10 reverse split in August. The agreement signals growing demand for Scinai's manufacturing services, though the customer and timeline are not disclosed.
At the time of this announcement, SCNI was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $661.2K. The 52-week trading range was $1.06 to $15.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.